Title : Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.

Pub. Date : 2011 May

PMID : 21266595






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In contrast, midazolam 1"-hydroxylation catalyzed by recombinant CYP3A5 was enhanced by the coexistence of sorafenib or sunitinib in a concentration-dependent manner, with saturation occurring at approximately 10 muM. Midazolam latexin Homo sapiens